The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 31, 2018

Filed:

May. 10, 2016
Applicant:

Rheinische Friedrich-wilhelms-universität Bonn, Bonn, DE;

Inventors:

Gunther Hartmann, Bonn, DE;

Martin Schlee, Bonn-Bad Godesberg, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/117 (2010.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); C12N 15/113 (2010.01); A61K 31/7088 (2006.01); C07H 21/00 (2006.01); A61K 31/713 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1135 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C07H 21/00 (2013.01); C12N 15/113 (2013.01); C12N 15/117 (2013.01); C12N 15/1131 (2013.01); C12N 2310/14 (2013.01); C12N 2310/17 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01);
Abstract

The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5' triphosphate, and at least one blunt end which bears a 5′ triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.


Find Patent Forward Citations

Loading…